Oral magnesium supplements for cancer treatment-induced hypomagnesemia: Results from a pilot randomized trial
Awan A, Basulaiman B, Stober C, Clemons M, Fergusson D, Hilton J, Al Ghareeb W, Goodwin R, Ibrahim M, Hutton B, Vandermeer L, Mallick R, Vickers MM
Health science reports · 6 citas
Etiquetas de revisión
Vínculos de autores con la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Autores
- Al menos un autor declara un vínculo económico con la industria
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2021-12-01 · Health Sci Rep · vol. 4 · número 4 · pág. e443
- Editorial
- Wiley
- Citado
- 8 citas · más que el 63% de estudios similares · 0.6× el promedio de su campo
- Referencias
- 25 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Magnesium in Health and Disease · Parathyroid Disorders and Treatments · Potassium and Related Disorders
- Palabras clave
- Medicine, Randomized controlled trial, Hypomagnesemia, Tolerability, Internal medicine, Magnesium, Adverse effect
13 autores
- Arif Ali Awan🇨🇦Ottawa Hospital
- Bassam Mohammed Basulaiman🇨🇦Ottawa Hospital
- Carol Stober🇨🇦Ontario Institute for Cancer Research; Ottawa Hospital; Ottawa Hospital Research Institute
- Mark J. Clemons🇨🇦Ontario Institute for Cancer Research; University of Ottawa; Ottawa Hospital; Ottawa Hospital Research Institute
- Dean A. Fergusson🇨🇦University of Ottawa; Ottawa Hospital; Ottawa Hospital Research Institute
- John Frederick Hilton🇨🇦Ontario Institute for Cancer Research; Ottawa Hospital; Ottawa Hospital Research Institute
- Waleed Al Ghareeb🇨🇦Ottawa Hospital
- Rachel Anne Goodwin🇨🇦Ottawa Hospital
- Mohammed F. K. Ibrahim🇨🇦Ottawa Hospital
- Brian F. Hutton🇨🇦Ottawa Hospital; Ottawa Hospital Research Institute
- Lisa Vandermeer🇨🇦Ontario Institute for Cancer Research; Ottawa Hospital; Ottawa Hospital Research Institute
- Ranjeeta Mallick🇨🇦Ottawa Hospital; Ottawa Hospital Research Institute
- Michael M. Vickers🇨🇦 · autor de correspondenciaUniversity of Ottawa; Ottawa Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background and aims
Optimal management of cancer treatment-induced hypomagnesemia (hMg) is not known. We assessed the feasibility of using a novel pragmatic clinical trials model to compare two commonly used oral Mg replacement strategies.
Methods
Patients with grade 1 to 3 hMg while receiving either platinum-based chemotherapy or epidermal growth factor receptor inhibitors (EGFRI) were randomized to oral magnesium oxide (MgOx) or oral magnesium citrate (MgCit). The trial methodology utilized the integrated consent model. Feasibility would be successful if; accrual rate was ≥5 patients a month and if measures of patient and physician engagement, were > 50%. Secondary endpoints included; comparison of Mg levels, cardiac arrhythmias, and rates of treatment delay/hospitalizations.
Results
From July 2016 to December 2017, an average of 1 patient a month was accrued. All 15 eligible and approached patients consented to participate in the study (100% engagement) and 7/15 were randomized to MgOx and 8/15 to MgCit. The percentage of physicians who approached patients for the study was 4 of 6 (66.6% engagement). The mean slope of change in Mg (mmol/L/day) was 0.0022 (95% CI: -0.0001 to 0.0044) for MgOx and 0.0006 (95% CI, -0.0012 to 0.0024) for MgCit (P = .2123). Three patients (20%) required IV magnesium while on the study (2 MgCit and 1 MgOx). Grade 1 diarrhea occurred in 3 patients in the MgCit arm.
Conclusion
Despite oral magnesium tolerability and meeting most of its feasibility endpoints, this study did not meet its target accrual rate. Alternative designs would be necessary for a definitive efficacy study.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.